Market open
Monopar Therapeutics Inc./$MNPR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Ticker
$MNPR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
15
ISIN
US61023L2079
Website
MNPR Metrics
BasicAdvanced
$215M
-
-$4.11
1.02
-
Price and volume
Market cap
$215M
Beta
1.02
52-week high
$47.83
52-week low
$26.06
Average daily volume
22K
Financial strength
Current ratio
11.475
Quick ratio
11.46
Management effectiveness
Return on assets (TTM)
-29.87%
Return on equity (TTM)
-51.42%
Valuation
Price to book
3.89
Price to tangible book (TTM)
3.89
Price to free cash flow (TTM)
-20.773
Growth
Earnings per share change (TTM)
35.32%
3-year earnings per share growth (CAGR)
4.06%
MNPR News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Monopar Therapeutics Inc. stock?
Monopar Therapeutics Inc. (MNPR) has a market cap of $215M as of May 13, 2025.
What is the P/E ratio for Monopar Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Monopar Therapeutics Inc. (MNPR) stock is 0 as of May 13, 2025.
Does Monopar Therapeutics Inc. stock pay dividends?
No, Monopar Therapeutics Inc. (MNPR) stock does not pay dividends to its shareholders as of May 13, 2025.
When is the next Monopar Therapeutics Inc. dividend payment date?
Monopar Therapeutics Inc. (MNPR) stock does not pay dividends to its shareholders.
What is the beta indicator for Monopar Therapeutics Inc.?
Monopar Therapeutics Inc. (MNPR) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.